Published online Jun 27, 2022. doi: 10.4240/wjgs.v14.i6.629
Peer-review started: November 23, 2021
First decision: January 12, 2022
Revised: January 15, 2022
Accepted: June 13, 2022
Article in press: June 13, 2022
Published online: June 27, 2022
Processing time: 215 Days and 13.6 Hours
Transplant recipients usually have increased chances of graft rejection and graft vs host disease, requiring chronic immunosuppressive therapy. Nonetheless, long-term immunosuppression risks malignancies such as skin cancer, lymphoma, and Kaposi sarcoma. However, there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy. “Immunotherapy after liver transplantation: Where are we now?” is a study, where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients. The authors reported the graft rejection rates and the factors contributing to the rejection in the liver transplant recipients.
Core Tip: There is an increased risk of cancer among transplant recipients receiving chronic immunosuppression. Immunotherapy has a beneficiary effect over immunosuppressors in reducing the overall cancer risk. However, there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy. “Immunotherapy after liver transplantation: Where are we now?” is a study, where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients.